Asthma

Respiratory 9 original drugs

Novel Drugs

Reformulations

Drug Targets

Respiratory indication. Asthma has 9 FDA-approved novel treatments, led by GSK, with 185 active industry clinical trials across 21 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Asthma Market Leaders

Companies with the most FDA-approved novel Asthma drugs.

Phase 3 Readouts Pro

12 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q4 2026

—

AstraZeneca

Estimated · fresh NCT06471257

Q4 2026

TEV-56248

Teva Branded Pharmaceutical Products R&D LLC

Estimated · fresh NCT06052267

Q1 2027

FF/UMEC/VI

GSK

Estimated · aging NCT05757102

Unlock 9 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Asthma Treatments by Mechanism

Top 12 mechanisms across 95 industry trials with a known mechanism of action.

See full pipeline →

Interleukin-4 Receptor alpha Antagonist

12 trials 3 active 2 sponsors

Interleukin-5 Receptor alpha-directed Cytolytic Antibody

20 trials 2 active 2 sponsors

Interleukin-5 Antagonist

15 trials 1 active 3 sponsors

Glucocorticoid receptor

14 trials 4 sponsors

Anti-IgE

12 trials 5 sponsors

Corticosteroid

8 trials 4 sponsors

Beta-2 adrenergic receptor/Glucocorticoid receptor

7 trials 5 sponsors

Interleukin-13 Antagonist

2 trials 1 sponsor

M1 receptor/M2 receptor/M3 receptor/M4 receptor/M5 receptor

2 trials 1 sponsor

Glucocorticoid receptor/beta 2-adrenergic receptor

1 trials 1 sponsor

Adenosine Receptor Agonist

1 trials 1 sponsor

Beta-2 adrenergic receptor/Muscarinic receptors

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Asthma Clinical Pipeline by Phase

888 industry-sponsored trials across 189 sponsors

View full landscape →

Showing 68 of 68 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
AstraZeneca	Benralizumab	Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]	ACTIVE NOT RECRUITING	2026-10-19	NCT03953300
Sanofi	Dupilumab	Interleukin-4 Receptor alpha Antagonist [EPC]	ACTIVE NOT RECRUITING	2027-03-16	NCT05097287
AstraZeneca	Albuterol and budesonide inhalation aerosol	—	ACTIVE NOT RECRUITING	2027-03-31	NCT06422689
Regeneron	dupilumab	Interleukin-4 Receptor alpha Antagonist [EPC]	ACTIVE NOT RECRUITING	2027-04-24	NCT06572228
GSK	Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate	—	ACTIVE NOT RECRUITING	2025-07-28	NCT06372496
GSK	Mepolizumab	Interleukin-5 Antagonist [EPC]	ACTIVE NOT RECRUITING	2025-01-31	NCT06041386
Chiesi Farmaceutici S.p.A.	Beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide (100/6/12.5 µg per actuation)	—	NOT YET RECRUITING	2028-06-13	NCT07666490
AstraZeneca	Tezepelumab	—	COMPLETED	2025-10-01	NCT05329194
Sanofi	Dupilumab	Interleukin-4 Receptor alpha Antagonist [EPC]	COMPLETED	2024-10-16	NCT04998604
AstraZeneca	—	—	COMPLETED	2024-09-03	NCT05440097
AstraZeneca	—	—	COMPLETED	2024-07-19	NCT05552508
Orion Corporation, Orion Pharma	—	—	COMPLETED	2024-04-24	NCT04869384
GSK	Mepolizumab	Interleukin-5 Antagonist [EPC]	COMPLETED	2023-10-28	NCT04276233
Sanofi	SAR231893	—	COMPLETED	2023-10-03	NCT04502862
Regeneron	dupilumab	Interleukin-4 Receptor alpha Antagonist [EPC]	COMPLETED	2023-07-15	NCT04203797
AstraZeneca	Benralizumab	Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]	COMPLETED	2023-07-01	NCT05384938
Orion Corporation, Orion Pharma	Buventol® Easyhaler® 200 µg/inhalation dmDPI	—	COMPLETED	2023-06-30	NCT05084222
Sanofi	Dupilumab	Interleukin-4 Receptor alpha Antagonist [EPC]	COMPLETED	2023-06-26	NCT04400318
AstraZeneca	Symbicort®	—	COMPLETED	2023-01-31	NCT04159519
AstraZeneca	—	—	COMPLETED	2022-12-16	NCT03924635
Teva Branded Pharmaceutical Products R&D, Inc.	Fluticasone propionate/salmeterol (FS)	—	COMPLETED	2022-03-04	NCT04677959
Teva Branded Pharmaceutical Products R&D, Inc.	Albuterol eMDPI DS	—	COMPLETED	2021-10-04	NCT03890666
GSK	—	—	COMPLETED	2021-07-08	NCT04813354
Intech Biopharm Ltd.	Budesonide 200 microgram/Puff, HFA MDI	—	COMPLETED	2021-05-09	NCT05152355
GSK	Fluticasone furoate	Glucocorticoid receptor	COMPLETED	2021-04-09	NCT02889809
Amphastar Pharmaceuticals, Inc.	—	—	COMPLETED	2019-12-20	NCT04207840
GSK	ACT guided Routine Treatment	—	COMPLETED	2019-08-09	NCT02868281
GSK	RELVAR/BREO	—	COMPLETED	2019-01-24	NCT03380429
GSK	Placebo DPI	—	COMPLETED	2018-12-07	NCT03478657
PharmEvo Pvt Ltd	Montelukast	—	COMPLETED	2017-12-30	NCT03096327
Roche	FP	—	COMPLETED	2017-07-10	NCT02537691
Asthma Management Systems	Dulera	Glucocorticoid receptor/beta 2-adrenergic receptor	COMPLETED	2017-07-01	NCT02045875
GSK	Mepolizumab 100mg SC	—	COMPLETED	2017-05-31	NCT02654145
GSK	Fluticasone furoate/ Vilanterol 100 mcg/25 mcg	—	COMPLETED	2017-02-03	NCT02730351
GSK	—	—	COMPLETED	2016-12-15	NCT02794480
Organon and Co	Mometasone Furoate/Formoterol MDI 100/5 mcg	—	COMPLETED	2016-11-30	NCT01471340
Menarini International Operations Luxembourg SA	Bilastine 20mg	—	COMPLETED	2016-11-24	NCT02761252
Hanmi Pharmaceutical Company Limited	one-way education	—	COMPLETED	2016-09-01	NCT03110874
GSK	FP/ SLM HFA MDI 50/25 mcg	—	COMPLETED	2016-06-01	NCT02113436
Roche	Omalizumab	Anti-IgE [EPC]	COMPLETED	2016-03-31	NCT01922037
GSK	Placebo ELLIPTA inhaler	—	COMPLETED	2016-02-04	NCT02586506
GSK	NEUMOTEROL 400 (BFF 400/12 mcg) single capsule inhaler	—	COMPLETED	2015-12-11	NCT02233803
GSK	ADVAIR 100/50mcg	—	COMPLETED	2015-11-01	NCT01462344
GSK	—	—	COMPLETED	2015-08-20	NCT02416180
GSK	ADVAIR 100/50mcg	—	COMPLETED	2015-06-23	NCT01475721
GSK	—	—	COMPLETED	2015-05	NCT02195284
Eisai Co., Ltd.	lysozyme 90 mg	—	COMPLETED	2013-12	NCT01715493
Roche	Omalizumab	Anti-IgE [EPC]	COMPLETED	2013-08	NCT01125748
Cornerstone Therapeutics Inc.	Zileuton extended release	—	COMPLETED	2013-06	NCT01805687
Mundipharma AB	Mannitol challenge test & reversibility test	—	COMPLETED	2012-04	NCT01449123
Novartis	omalizumab at a dose of 0.016mg/kg/IU/mL	—	COMPLETED	2011-11	NCT00670930
GSK	FLOVENT™ DISKUS™ 100 mcg BID	—	COMPLETED	2010-12	NCT01192178
Grünenthal Colombiana S.A.	Beclomethasone	—	COMPLETED	2010-12	NCT01333800
AstraZeneca	Symbicort (Budesonide/Formoterol)	—	COMPLETED	2010-08	NCT00939341
AstraZeneca	Ciclesonide	Glucocorticoid receptor	COMPLETED	2010-07	NCT00826969
GSK	—	—	COMPLETED	2010-04	NCT00858286
Novartis	Omalizumab	Anti-IgE [EPC]	COMPLETED	2010-03	NCT00870584
Astellas	Regadenoson	Adenosine Receptor Agonist [EPC]	COMPLETED	2009-10	NCT00862641
AstraZeneca	Budesonide / formoterol fumarate (SYMBICORT)	—	COMPLETED	2009-09	NCT00702325
Roche	Cohort I	—	COMPLETED	2009-04	NCT00777764
Novartis	Xolair	Anti-IgE [EPC]	COMPLETED	2009-01	NCT00624832
AstraZeneca	Symbicort Turbuhaler 160/4.5	—	COMPLETED	—	NCT00576316
Chiesi Farmaceutici S.p.A.	Administration via pressurized metered dose inhaler (pMDI)	—	TERMINATED	2024-04-16	NCT05018598
Roche	Omalizumab	Anti-IgE [EPC]	TERMINATED	2021-10-18	NCT04195958
Teva Branded Pharmaceutical Products R&D, Inc.	Reslizumab	Interleukin-5 Antagonist [EPC]	TERMINATED	2017-05-24	NCT02937168
Mundipharma Korea Ltd	Fluticasone/Formoterol	—	TERMINATED	2017-04-06	NCT02491970
GSK	Fluticasone Furoate/Vilanterol	—	WITHDRAWN	2019-05-29	NCT03363191
Novartis	Foradil Combi (Formoterol-budesonide)	—	WITHDRAWN	2010-07	NCT00997477

Showing 100 of 260 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Teva Branded Pharmaceutical Products R&D LLC	Fp/ABS	—	RECRUITING	2026-09-19	NCT06664619
AstraZeneca	—	—	RECRUITING	2026-10-30	NCT06471257
GSK	FF/UMEC/VI	—	RECRUITING	2027-01-15	NCT05757102
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	610	—	RECRUITING	2027-02	NCT06323213
AstraZeneca	Tezepelumab	—	RECRUITING	2027-08-07	NCT07363642
AstraZeneca	—	—	RECRUITING	2027-10-13	NCT06307665
Shanghai Mabgeek Biotech.Co.Ltd	MG-K10/Placebo	—	RECRUITING	2027-11-15	NCT06837922
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.	TQC2731 injection	—	RECRUITING	2027-12	NCT06829784
GSK	Depemokimab	—	RECRUITING	2027-12-08	NCT06979323
Guangdong Hengrui Pharmaceutical Co., Ltd	SHR-1905 Injection	—	RECRUITING	2028-01	NCT07098403
Novartis	QMF149	—	RECRUITING	2028-02-01	NCT05562466
AstraZeneca	Tezepelumab	—	RECRUITING	2028-05-31	NCT06023589
Generate Biomedicines	GB-0895	—	RECRUITING	2028-12	NCT07276724
Sanofi	Dupilumab	Interleukin-4 Receptor alpha Antagonist [EPC]	RECRUITING	2028-12-21	NCT06191315
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.	CM326	—	RECRUITING	2028-12-31	NCT07372287
Generate Biomedicines	GB-0895	—	RECRUITING	2029-01	NCT07359846
AstraZeneca	Benralizumab	Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]	RECRUITING	2030-05-05	NCT05692180
GSK	Depemokimab	—	RECRUITING	2030-07-08	NCT07456033
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	CM310	—	RECRUITING	2032-05	NCT05761028
Teva Branded Pharmaceutical Products R&D LLC	TEV-56248	—	ACTIVE NOT RECRUITING	2026-10-31	NCT06052267
AstraZeneca	—	—	ACTIVE NOT RECRUITING	2027-06-25	NCT06473779
AstraZeneca	BDA MDI HFO 160/180 μg	—	ACTIVE NOT RECRUITING	2026-03-03	NCT06502366
GSK	HFA-152a	—	NOT YET RECRUITING	2027-02-25	NCT07645248
Chiesi Farmaceutici S.p.A.	Experimental: Participant Group CHF 5993 pMDI HFA-152a	—	NOT YET RECRUITING	2028-10-17	NCT07546981
Qilu Pharmaceutical Co., Ltd.	tezepelumab (Arm1&Arm2)	—	NOT YET RECRUITING	2028-12	NCT07302516
Novartis	QVM149	—	NOT YET RECRUITING	2028-12-21	NCT05776927
GSK	Depemokimab	—	NOT YET RECRUITING	2029-03-19	NCT07671001
AstraZeneca	Benralizumab	Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]	NOT YET RECRUITING	2029-12-28	NCT07444567
Inmunotek S.L.	3,000 MM09	—	NOT YET RECRUITING	2026-06-01	NCT05641272
GSK	GSK3511294 (Depemokimab)	—	COMPLETED	2025-09-14	NCT04718389
GSK	Salbutamol HFA-134a	—	COMPLETED	2025-09-02	NCT06261957
GSK	GSK3511294 (Depemokimab)	—	COMPLETED	2025-05-19	NCT05243680
Sanofi	Dupilumab (SAR231893/REGN668)	—	COMPLETED	2025-04-01	NCT03560466
AstraZeneca	BGF MDI 320/28.8/9.6 μg	—	COMPLETED	2025-03-21	NCT04609878
AstraZeneca	BGF MDI 320/28.8/9.6 μg	—	COMPLETED	2025-03-20	NCT04609904
AstraZeneca	BFF MDI 320/9.6 μg	—	COMPLETED	2025-02-26	NCT05202262
Chiesi Farmaceutici S.p.A.	CHF5993 200/6/12.5 μg pMDI HFA-152a	—	COMPLETED	2025-02-18	NCT06264674
AstraZeneca	BFF MDI 160/9.6 μg BID (320/19.2μg/day)	—	COMPLETED	2024-11-19	NCT05755906
AstraZeneca	—	—	COMPLETED	2024-11-18	NCT05555290
Cipla Ltd.	Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation)	—	COMPLETED	2024-09-16	NCT06154304
AstraZeneca	Tezepelumab	—	COMPLETED	2024-09-09	NCT05274815
Bond Avillion 2 Development LP	BDA MDI	—	COMPLETED	2024-08-22	NCT05505734
GSK	FF/VI	—	COMPLETED	2024-08-05	NCT04937387
Chiesi Farmaceutici S.p.A.	Beclomethasone Dipropionate/Formoterol Fumarate	—	COMPLETED	2024-06-24	NCT05292586
AstraZeneca	Experimental: Tezepelumab	—	COMPLETED	2024-05-24	NCT03927157
GSK	GSK3511294	—	COMPLETED	2024-04-11	NCT04718103
GSK	GSK3511294 (Depemokimab)	—	COMPLETED	2023-11-21	NCT04719832
AstraZeneca	HFA MDI	—	COMPLETED	2023-08-21	NCT05850494
Cipla Ltd.	Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg	—	COMPLETED	2023-08-15	NCT05322707
Chiesi Farmaceutici S.p.A.	Beclomethasone dipropionate 100 µg / Formoterol fumarate 6 µg (Inhaler A)	—	COMPLETED	2023-02-01	NCT04886999
AstraZeneca	Benralizumab	Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]	COMPLETED	2023-01-30	NCT03186209
Cinnagen	Omalizumab (CinnaGen)	—	COMPLETED	2023-01-15	NCT05813470
GSK	Mepolizumab 100 milligrams	—	COMPLETED	2022-09-07	NCT03562195
Sanofi	Dupilumab SAR231893	—	COMPLETED	2022-05-21	NCT03782532
ALK-Abelló A/S	HDM SLIT-tablet	—	COMPLETED	2022-05-18	NCT03654976
GSK	FF/VI via ELLIPTA DPI	—	COMPLETED	2022-03-21	NCT03248128
AstraZeneca	Tezepelumab	—	COMPLETED	2022-03-21	NCT05062759
Sanofi	Dupilumab SAR231893 (REGN668)	—	COMPLETED	2022-02-18	NCT03620747
Chiesi Farmaceutici S.p.A.	Foster 100/6mg NEXThaler	—	COMPLETED	2021-12-28	NCT03453112
AstraZeneca	Tezepelumab	—	COMPLETED	2021-10-26	NCT03706079
Bond Avillion 2 Development LP	Albuterol sulfate metered-dose inhaler 180 μg	—	COMPLETED	2021-08-19	NCT03769090
Respirent Pharmaceuticals Co Ltd.	Fluticasone propionate 100 mcg/blister oral inhalation powder/Respirent Pharmaceuticals	—	COMPLETED	2021-08-13	NCT04665895
Bond Avillion 2 Development LP	Budesonide metered dose inhaler / BD MDI 160 µg	—	COMPLETED	2021-07-20	NCT03847896
Actavis Inc.	Fluticasone propionate pressurized metered dose inhaler	—	COMPLETED	2021-05-28	NCT03879837
AstraZeneca	Benralizumab	Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]	COMPLETED	2021-04-16	NCT03557307
AstraZeneca	Biological: Experimental: Tezepelumab	—	COMPLETED	2021-03-18	NCT04048343
AstraZeneca	Tezepelumab	—	COMPLETED	2020-09-25	NCT03406078
AstraZeneca	Experimental: Tezepelumab	—	COMPLETED	2020-09-08	NCT03347279
AB Science	Masitinib	—	COMPLETED	2020-09	NCT03771040
Sanofi	Dupilumab	Interleukin-4 Receptor alpha Antagonist [EPC]	COMPLETED	2020-08-26	NCT02948959
AstraZeneca	Benralizumab	Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]	COMPLETED	2020-06-18	NCT02808819
AstraZeneca	Tezepelumab (APFS)	—	COMPLETED	2020-06-05	NCT03968978
Cipla Ltd.	Fluticasone propionate/salmeterol 100/50 µg	—	COMPLETED	2019-12-03	NCT03394989
AB Science	Masitinib	—	COMPLETED	2019-11	NCT01449162
Actavis Inc.	Fluticasone Propionate and Salmeterol Inhalation Powder	—	COMPLETED	2019-10-26	NCT03756883
AstraZeneca	Benralizumab	Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]	COMPLETED	2019-10-22	NCT02821416
Novartis	QAW039	—	COMPLETED	2019-10-21	NCT02555683
Sanofi	Dupilumab	Interleukin-4 Receptor alpha Antagonist [EPC]	COMPLETED	2019-10-11	NCT02134028
AstraZeneca	Benralizumab (Medi-563)	—	COMPLETED	2019-09-25	NCT03170271
Pearl Therapeutics, Inc.	GP MDI 28.8 μg	—	COMPLETED	2019-09-12	NCT03358147
Aurobindo Pharma Ltd	Test Product	—	COMPLETED	2019-08-29	NCT04051710
Respirent Pharmaceuticals Co Ltd.	Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals	—	COMPLETED	2019-08-02	NCT03676413
GSK	Mepolizumab 100mg	—	COMPLETED	2019-07-24	NCT02555371
Novartis	QVM149	—	COMPLETED	2019-07-12	NCT03158311
Novartis	QAW039	—	COMPLETED	2019-07-05	NCT03226392
Novartis	QAW039	—	COMPLETED	2019-07-04	NCT02563067
Novartis	QAW039	—	COMPLETED	2019-07-02	NCT03215758
GSK	FF/UMEC/VI 100/62.5/25 mcg	—	COMPLETED	2019-06-25	NCT03184987
Novartis	QVM149 150/50/160	—	COMPLETED	2019-06-14	NCT02571777
AO GENERIUM	Genolar® + Symbicort®	—	COMPLETED	2019-04-29	NCT04607629
Teva Branded Pharmaceutical Products R&D, Inc.	Fluticasone Propionate	Beta-2 adrenergic receptor/Glucocorticoid receptor	COMPLETED	2019-04-07	NCT02980133
Sun Pharmaceutical Industries Limited	Zero-dose	—	COMPLETED	2019-03-11	NCT03528577
GSK	FF/UMEC/VI (100/31.25/25) mcg	—	COMPLETED	2019-02-22	NCT02924688
Xemed LLC	HXe MRI guided treatment sequence for BT	—	COMPLETED	2018-12	NCT01832363
Novartis	Indacaterol acetate/Mometasone furoate	—	COMPLETED	2018-11-21	NCT02554786
Novartis	QVM149	—	COMPLETED	2018-09-18	NCT03100825
AstraZeneca	Benralizumab	Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]	COMPLETED	2018-08-01	NCT02869438
Novartis	QMF149	—	COMPLETED	2018-07-19	NCT03100500
Actavis Inc.	Generic Budesonide/Formoterol Fumarate Dihydrate	—	COMPLETED	2018-05-31	NCT02495168
Chiesi Farmaceutici S.p.A.	CHF 5993 200/6/12.5 µg	—	COMPLETED	2018-05-28	NCT02676089

Showing 100 of 339 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Enveda Therapeutics	ENV-294	—	RECRUITING	2026-12	NCT07301255
Pfizer	PF-07275315	—	RECRUITING	2027-03-08	NCT06977581
Chiesi Farmaceutici S.p.A.	CHF5993 pMDI with HFA-152a	—	RECRUITING	2027-06-03	NCT07301736
AstraZeneca	Tozorakimab	—	RECRUITING	2027-06-24	NCT06932263
Keymed Biosciences Co.Ltd	CM512 injection	—	RECRUITING	2027-07-21	NCT07011524
Novartis	Glycopyrronium bromide 25ug	—	RECRUITING	2027-07-30	NCT05222529
Shanghai Novamab Biopharmaceuticals Co., Ltd.	LQ036	—	RECRUITING	2027-09	NCT07589439
Sanofi	Lunsekimig	—	RECRUITING	2027-09-17	NCT06676319
Arrowhead Pharmaceuticals	ARO-RAGE	—	RECRUITING	2027-12	NCT07241546
Oneness Biotech Co., Ltd.	FB825	—	RECRUITING	2027-12	NCT05008965
Longbio Pharma	LP-003 Injection	—	RECRUITING	2027-12-28	NCT07342803
Eli Lilly	Brenipatide	—	RECRUITING	2028-04	NCT07219173
AstraZeneca	—	—	RECRUITING	2029-05-23	NCT07525375
Incyte Corporation	povorcitinib	—	RECRUITING	2026-06-15	NCT05851443
Anhui Palo Alto Pharmaceuticals, Inc.	PA9159 Metered-Dose Inhaler, 120 μg per day for 28 days	—	RECRUITING	2026-03	NCT07324707
Oneness Biotech Co., Ltd.	FB704A	—	RECRUITING	2026-02-13	NCT05018299
Anhui Palo Alto Pharmaceuticals, Inc.	PA9159 Metered-Dose Inhaler, 60 μg per day for 28 days	—	RECRUITING	2026-02	NCT07326995
GSK	GSK5784283	—	ACTIVE NOT RECRUITING	2026-07-17	NCT06748053
Sanofi	Amlitelimab	—	ACTIVE NOT RECRUITING	2026-09-29	NCT06033833
Shanghai Hengrui Pharmaceutical Co., Ltd.	SHR-1905	—	ACTIVE NOT RECRUITING	2026-12-30	NCT05593250
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	610	—	ACTIVE NOT RECRUITING	2027-02	NCT06680947
Upstream Bio Inc.	Verekitug	—	ACTIVE NOT RECRUITING	2027-09	NCT06966479
Uniquity One (UNI)	NSI-8226	—	ACTIVE NOT RECRUITING	2026-06-30	NCT06496607
Shanghai Mabgeek Biotech.Co.Ltd	MG-ZG122 Humanized Monoclonal Antibody Injection	—	ACTIVE NOT RECRUITING	2026-05-26	NCT07054034
Amgen	Rocatinlimab	—	ACTIVE NOT RECRUITING	2026-05-14	NCT06376045
Akeso	AK139	—	NOT YET RECRUITING	2026-12-27	NCT07436221
Foresee Pharmaceuticals Co., Ltd.	linvemastat	—	NOT YET RECRUITING	2027-01-01	NCT07191535
Nanjing RegeneCore Biotech Co., Ltd.	RC1416	—	NOT YET RECRUITING	2027-10-25	NCT07403487
Kinaset Therapeutics Inc	Frevecitinib	—	NOT YET RECRUITING	2027-11-30	NCT07532265
Guangdong Hengrui Pharmaceutical Co., Ltd	SHR4597	—	NOT YET RECRUITING	2025-10	NCT06940700
Sanofi	Lunsekimig	—	COMPLETED	2026-02-23	NCT06102005
AstraZeneca	AZD8630	—	COMPLETED	2026-02-04	NCT06529419
AstraZeneca	Atuliflapon	—	COMPLETED	2026-01-07	NCT05251259
Upstream Bio Inc.	Verekitug (UPB-101)	—	COMPLETED	2025-12-16	NCT06196879
Jemincare	JYB1904	—	COMPLETED	2025-11-20	NCT06438757
AstraZeneca	AZD4604	—	COMPLETED	2025-10-28	NCT06020014
AstraZeneca	AZD4604	—	COMPLETED	2025-10-15	NCT06435273
Chiesi Farmaceutici S.p.A.	CHF 6001	—	COMPLETED	2025-08-11	NCT06900816
AstraZeneca	—	—	COMPLETED	2025-06-04	NCT06644924
Arrowhead Pharmaceuticals	ARO-RAGE	—	COMPLETED	2025-04-16	NCT05276570
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	TQC2731 injection	—	COMPLETED	2025-03-05	NCT05472324
Sanofi	Amlitelimab	—	COMPLETED	2024-10-11	NCT05421598
Beijing Kanova Biopharmaceutical Co., LTD	XKH001 Injection	—	COMPLETED	2024-02-20	NCT05991661
Sanofi	Rilzabrutinib	Kinase Inhibitor [EPC]	COMPLETED	2024-02-06	NCT05104892
ARS Pharmaceuticals, Inc.	ARS-1	—	COMPLETED	2024-02-02	NCT05363670
Keymed Biosciences Co.Ltd	CM310	—	COMPLETED	2023-09-13	NCT05186909
Aquilon Pharmaceuticals S.A.	AQ001S 0.125 mg/ml	—	COMPLETED	2022-12-31	NCT04933383
AstraZeneca	MEDI3506	—	COMPLETED	2022-12-12	NCT04570657
Chiesi Farmaceutici S.p.A.	Placebo 152a	—	COMPLETED	2022-10-31	NCT05472662
Roche	MTPS9579A	—	COMPLETED	2022-05-19	NCT04092582
Novartis	Mometasone furoate	Glucocorticoid receptor	COMPLETED	2022-04-11	NCT04589663
T-Balance Therapeutics GmbH	Tregalizumab	—	COMPLETED	2022-01-12	NCT04673591
Tetherex Pharmaceuticals Corporation	SelK2 (Part 1)	—	COMPLETED	2021-12-21	NCT04540042
Chemlmmune Therapeutics LLC	XC8 100 mg	—	COMPLETED	2021-08-27	NCT04674137
Knopp Biosciences	Dexpramipexole	—	COMPLETED	2020-12-03	NCT04046939
AstraZeneca	Tezepelumab	—	COMPLETED	2020-11-16	NCT03688074
Theravance Biopharma	TD-8236	—	COMPLETED	2020-08-28	NCT04150341
GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.	GB001	—	COMPLETED	2020-07-23	NCT03683576
Palobiofarma SL	PBF-680	—	COMPLETED	2020-02-05	NCT03774290
AstraZeneca	AZD7594 DPI 55μg/50μg.	—	COMPLETED	2019-09-30	NCT03622112
Palobiofarma SL	PBF-680	—	COMPLETED	2019-09-30	NCT02635945
Novartis	Indacaterol acetate 75 μg	—	COMPLETED	2019-06-19	NCT02892019
Chiesi Farmaceutici S.p.A.	CHF6366	—	COMPLETED	2019-04-16	NCT03378648
Novartis	CJM112	—	COMPLETED	2019-04-08	NCT03299686
Roche	MSTT1041A	—	COMPLETED	2019-04-05	NCT02918019
Sanofi	SAR440340	—	COMPLETED	2019-03-21	NCT03387852
GSK	GSK3772847	—	COMPLETED	2019-02-15	NCT03207243
GSK	Fluticasone furoate (FF) Dry Powder Inhaler	—	COMPLETED	2018-12-20	NCT02991859
Chiesi Farmaceutici S.p.A.	CHF 718 pMDI	—	COMPLETED	2018-11-28	NCT03084718
AstraZeneca	AZD1419	—	COMPLETED	2018-09-25	NCT02898662
Concentrx Pharmaceuticals, Inc.	Halix albuterol 90 mcg	—	COMPLETED	2018-08-31	NCT03643874
Novartis	QVM149 150/50/80 μg o.d.	—	COMPLETED	2018-08-02	NCT03063086
Chiesi Farmaceutici S.p.A.	CHF 1531 pMDI	—	COMPLETED	2018-07-23	NCT03086460
GSK	UMEC	—	COMPLETED	2018-05-30	NCT03012061
Laboratorios Leti, S.L.	DP/MG/14-1	—	COMPLETED	2018-05	NCT02340130
AstraZeneca	AS MDI 90 μg	—	COMPLETED	2018-03-30	NCT03364608
AstraZeneca	AS MDI	—	COMPLETED	2018-03-26	NCT03371459
Novartis	Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)	—	COMPLETED	2018-02-24	NCT03108027
GSK	GSK2245035 Nasal Spray Solution	—	COMPLETED	2018-02-14	NCT02833974
Novartis	Indacaterol maleate	—	COMPLETED	2018-01-17	NCT03257995
Sanofi	Dupilumab SAR231893/REGN668	—	COMPLETED	2018-01-03	NCT02573233
AbbVie	risankizumab	—	COMPLETED	2017-10-13	NCT02443298
PHARMENTERPRISES LLC	XC8 Oral Tablet	—	COMPLETED	2017-09-27	NCT03450434
Chiesi Farmaceutici S.p.A.	CHF1535 NEXThaler	—	COMPLETED	2017-09-19	NCT03108534
Merck	MK-1029 150 mg	—	COMPLETED	2017-08-16	NCT02720081
AstraZeneca	Tralokinumab	Interleukin-13 Antagonist [EPC]	COMPLETED	2017-06-21	NCT02449473
Chiesi Farmaceutici S.p.A.	CHF 1535 35/4µg NEXThaler®	—	COMPLETED	2017-06	NCT02787967
3-C Institute for Social Development	—	—	COMPLETED	2017-05	NCT02835300
GSK	Fluticasone furoate (FF) (100 mcg)	—	COMPLETED	2017-02-21	NCT02712047
RSPR Pharma AB	CRD007	—	COMPLETED	2017-02-21	NCT02615080
Roche	Lebrikizumab	—	COMPLETED	2016-12-20	NCT01987492
MedImmune LLC	MEDI9929 70 mg	—	COMPLETED	2016-12-12	NCT02054130
GSK	Mepolizumab	Interleukin-5 Antagonist [EPC]	COMPLETED	2016-12-07	NCT02377427
Biota Pharmaceuticals, Inc.	Vapendavir	—	COMPLETED	2016-12	NCT02367313
AstraZeneca	Interferon beta-1a Nebuliser solution 48 μg/mL	—	COMPLETED	2016-11-24	NCT02491684
Roche	Lebrikizumab	—	COMPLETED	2016-10-13	NCT02099656
Hvivo	PrEP-001	—	COMPLETED	2016-09	NCT03296917
Pearl Therapeutics, Inc.	Glycopyrronium MDI	—	COMPLETED	2016-03-26	NCT02433834
Theron Pharmaceuticals, Inc.	TRN-157	—	COMPLETED	2016-03	NCT02382510
AstraZeneca	800 μg AZD7594 once daily	—	COMPLETED	2016-02-08	NCT02479412

Showing 100 of 221 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
GSK	Salbutamol HFA-152a	—	RECRUITING	2027-02-26	NCT06433921
Apogee Therapeutics, Inc.	APG777	—	ACTIVE NOT RECRUITING	2026-09	NCT06920901
AstraZeneca	—	—	ACTIVE NOT RECRUITING	2026-10-23	NCT07433569
Amgen	AMG 691	—	ACTIVE NOT RECRUITING	2027-04-10	NCT06637371
Generate Biomedicines	GB-0895 (SC)	—	ACTIVE NOT RECRUITING	2027-05	NCT07116889
Pfizer	PF-08103402	—	NOT YET RECRUITING	2027-03-30	NCT07660731
AJU Pharm Co., Ltd.	AJU-R713	—	NOT YET RECRUITING	2025-12	NCT07231861
Innovent Biologics (Suzhou) Co. Ltd.	IBI3002	—	COMPLETED	2026-05-11	NCT06947408
SinoMab BioScience Ltd	SM17	—	COMPLETED	2026-02-03	NCT07466940
Nanjing RegeneCore Biotech Co., Ltd.	RC1416	—	COMPLETED	2025-09-25	NCT06911866
AstraZeneca	AZD8630	—	COMPLETED	2025-09-19	NCT07065331
Innovent Biologics (Suzhou) Co. Ltd.	IBI3002	—	COMPLETED	2025-07-22	NCT06213844
AstraZeneca	AZD8630	—	COMPLETED	2025-06-27	NCT06795906
GSK	HFA-152A propellant	—	COMPLETED	2025-06-04	NCT06702462
AstraZeneca	AZD4604	—	COMPLETED	2025-05-29	NCT06732882
OM Pharma SA	OM-85-IN	—	COMPLETED	2025-02-19	NCT06486662
GSK	—	—	COMPLETED	2024-10-24	NCT06506266
GSK	Salbutamol HFA-152a	—	COMPLETED	2024-10-18	NCT06433908
Teva Branded Pharmaceutical Products R&D, Inc.	TEV-56248	—	COMPLETED	2024-10-01	NCT06290102
Anhui Palo Alto Pharmaceuticals, Inc.	PA9159 Inhalation aerosol, 60 μg one day treatment	—	COMPLETED	2024-09-12	NCT06916273
AO GENERIUM	Genolair, solution for subcutaneous administration, 150 mg	—	COMPLETED	2024-06-09	NCT06494345
AstraZeneca	AZD4604 Inhalation Powder, 1 mg	—	COMPLETED	2024-05-20	NCT06157255
Arrowhead Pharmaceuticals	ARO-RAGE Injection	—	COMPLETED	2024-02-08	NCT05533294
Genrix (Shanghai) Biopharmaceutical Co., Ltd.	GR2002 injection	—	COMPLETED	2024-01-02	NCT05954611
CSL Behring	Human beta common receptor antagonist monoclonal antibody	—	COMPLETED	2023-11-14	NCT04082754
Harbour BioMed (Guangzhou) Co. Ltd.	HBM9378 (SKB378) Injection	—	COMPLETED	2023-10-24	NCT05790694
GSK	Depemokimab	—	COMPLETED	2023-10-23	NCT05602025
Chiesi Farmaceutici S.p.A.	CHF5993	—	COMPLETED	2023-10-13	NCT05830071
Shanghai Hengrui Pharmaceutical Co., Ltd.	SHR-1905/placebo	—	COMPLETED	2023-10-09	NCT04905602
SinoMab BioScience Ltd	SM17	—	COMPLETED	2023-09-26	NCT05332834
Upstream Bio Inc.	UPB-101	—	COMPLETED	2023-08-15	NCT05448651
AstraZeneca	AZD8630	—	COMPLETED	2023-08-02	NCT05110976
Chiesi Farmaceutici S.p.A.	Test product (T):CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI	—	COMPLETED	2023-07-14	NCT05898984
Bio-Thera Solutions	Mepolizumab Injection (BAT2606 Injection)	—	COMPLETED	2023-05-26	NCT05576454
GSK	Salbutamol HFA-152a	—	COMPLETED	2023-05-21	NCT05791565
Mabwell (Shanghai) Bioscience Co., Ltd.	Experimental drug 9MW1911	—	COMPLETED	2023-03-06	NCT05803902
Sanofi	SAR443765	—	COMPLETED	2023-02-24	NCT05366764
AstraZeneca	AZD4604 for inhalation via DPI	—	COMPLETED	2023-01-24	NCT04769869
GSK	Depemokimab	—	COMPLETED	2022-12-23	NCT05140200
Atridia Pty Ltd.	SHR-1905	—	COMPLETED	2022-11-12	NCT04800263
Keymed Biosciences Co.Ltd	CM326	—	COMPLETED	2022-10-11	NCT05171348
AstraZeneca	Tezepelumab	—	COMPLETED	2022-09-27	NCT04673630
Trio Medicines Ltd.	TR4	—	COMPLETED	2022-08-16	NCT07272135
Mabwell (Shanghai) Bioscience Co., Ltd.	9MW1911 Injection	—	COMPLETED	2022-07-03	NCT05170243
Evelo Biosciences, Inc.	EDP1867	—	COMPLETED	2022-02-28	NCT04927195
Shanghai Hengrui Pharmaceutical Co., Ltd.	SHR-1819	—	COMPLETED	2021-12-10	NCT04772365
TFF Pharmaceuticals, Inc.	Voriconazole Inhalation Powder	—	COMPLETED	2021-11-12	NCT04576325
Biocon Limited	EQ001	—	COMPLETED	2021-10-12	NCT04007198
Keymed Biosciences Co.Ltd	CM326	—	COMPLETED	2021-09-28	NCT04842201
Jiangsu HengRui Medicine Co., Ltd.	SHR-1703	—	COMPLETED	2021-09-21	NCT04480762
Bond Avillion 2 Development LP	BDA MDI (PT027) 160/180 μg	—	COMPLETED	2021-07-05	NCT04848662
AstraZeneca	AZD0449	—	COMPLETED	2021-06-24	NCT03766399
Taizhou Mabtech Pharmaceutical Co.,Ltd	Omalizumab	Anti-IgE [EPC]	COMPLETED	2021-04-26	NCT04778137
GSK	melrilimab (GSK3772847) 70 milligram (mg)	—	COMPLETED	2020-12-21	NCT04366349
KoBioLabs	KBL693	—	COMPLETED	2020-10-30	NCT04307173
Boehringer Ingelheim	BI 894416	—	COMPLETED	2020-10-26	NCT03971539
Pieris Australia Pty Ltd	PRS-060	—	COMPLETED	2020-09-15	NCT03574805
Theravance Biopharma	TD-8236	—	COMPLETED	2020-07-13	NCT03652038
AstraZeneca	AZD7594	—	COMPLETED	2020-07-09	NCT03976869
AstraZeneca	Tezepelumab	—	COMPLETED	2019-12-30	NCT03989544
AstraZeneca	AZD7594	—	COMPLETED	2019-11-28	NCT04072562
Chiesi Farmaceutici S.p.A.	Treatment A	—	COMPLETED	2019-11-22	NCT03942666
GSK	GSK3511294	—	COMPLETED	2019-07-31	NCT03287310
AstraZeneca	AZD8154	—	COMPLETED	2019-07-29	NCT03436316
Chiesi Farmaceutici S.p.A.	Therapeutic Dose 1	—	COMPLETED	2019-07-24	NCT03859414
Novartis	CSJ117	—	COMPLETED	2019-07-16	NCT03138811
AstraZeneca	Intravenous Infusion	—	COMPLETED	2019-07-05	NCT04002427
AstraZeneca	AZD1402	—	COMPLETED	2019-06-13	NCT03921268
Sunshine Lake Pharma Co., Ltd.	Litapiprant Tablet	—	COMPLETED	2019-01-30	NCT03663686
Regeneron	REGN3500	—	COMPLETED	2018-08-30	NCT02999711
Pulmatrix Inc.	Itraconazole Powder	—	COMPLETED	2018-06-28	NCT03479411
Concentrx Pharmaceuticals, Inc.	Albuterol DPI 90mcg	—	COMPLETED	2018-05-28	NCT03373409
Boehringer Ingelheim	BI 443651	—	COMPLETED	2018-02-07	NCT03135899
Peptinnovate	PIN201104	—	COMPLETED	2018-01	NCT03058458
Orion Corporation, Orion Pharma	salmeterol-fluticasone	—	COMPLETED	2017-12-19	NCT03238482
Intech Biopharm Ltd.	Budesonide	Corticosteroid [EPC]	COMPLETED	2017-11-17	NCT04494321
AstraZeneca	Abediterol	—	COMPLETED	2017-11-09	NCT03273127
GSK	GSK2292767 50 μg	—	COMPLETED	2017-08-11	NCT03045887
AstraZeneca	Benralizumab	Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]	COMPLETED	2017-07-13	NCT02968914
Vectura Limited	—	—	COMPLETED	2017-05-22	NCT04032834
EURRUS Biotech GmbH	XC8 (histamine glutarimide)	—	COMPLETED	2017-05	NCT02882217
AstraZeneca	Abediterol	—	COMPLETED	2017-04-06	NCT02967159
Chiesi Farmaceutici S.p.A.	Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium	—	COMPLETED	2017-03-21	NCT02975843
Johnson & Johnson	Part 1: CNTO 7160	—	COMPLETED	2017-03-16	NCT02345928
AstraZeneca	Abediterol 0.156 μg	—	COMPLETED	2016-11-29	NCT02777827
Orion Corporation, Orion Pharma	Salmeterol/fluticasone Easyhaler	—	COMPLETED	2016-11	NCT03060044
Zambon SpA	Z7200 without oral activated charcoal	—	COMPLETED	2016-07	NCT02631941
AstraZeneca	AZD7594 Solution for infusion (150 μg intravenous formulation)	—	COMPLETED	2016-06-01	NCT02648438
Teva Branded Pharmaceutical Products R&D, Inc.	Fluticasone Propionate MDPI	—	COMPLETED	2016-06	NCT02680561
MedImmune LLC	MEDI9929, 140 mg	—	COMPLETED	2016-05-17	NCT02512900
Intech Biopharm Ltd.	Budesonide	Corticosteroid [EPC]	COMPLETED	2016-05	NCT02850484
AstraZeneca	AZD7594 inhalation powder (200 μg)	—	COMPLETED	2016-04-17	NCT02645253
Vectura Limited	VR942 delivered via a Vectura Dry Powder Inhaler	—	COMPLETED	2016-04	NCT02473939
Orion Corporation, Orion Pharma	Budesonide/formoterol	—	COMPLETED	2016-03	NCT03073057
Amgen	AMG 282	—	COMPLETED	2016-03	NCT01928368
Acorda Therapeutics	CVT-301 (levodopa inhalation powder)	—	COMPLETED	2016-03	NCT02633007
Merck	RV16UB	—	COMPLETED	2015-12-25	NCT01866306
Orion Corporation, Orion Pharma	Salmeterol/fluticasone Easyhaler	—	COMPLETED	2015-09	NCT02162485
PHARMENTERPRISES LLC	XC8	—	COMPLETED	2015-07-07	NCT03441815
Teva Branded Pharmaceutical Products R&D, Inc.	Treatment A: Fp MDPI	—	COMPLETED	2015-07	NCT02437604

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Asthma

eosinophilic phenotype (2) IgE-mediated (1)

Novel Asthma Drugs by Company (New molecular entities)

5 companies have an FDA-approved novel drug for Asthma.

GSK 4 drugs

AstraZeneca 2 drugs

Roche 1 drug

Teva 1 drug

Regeneron 1 drug

Reformulations (24 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.

Asthma Drug Targets

Molecular targets of approved and investigational Asthma drugs — 21 targets tracked.

Glucocorticoid receptor 15 beta 2-adrenoceptor 3 Beta-2 adrenergic receptor 3 IL-5 3 FcεRI 2 IgE 2 adenyl cyclase 1 beta 2-adrenergic receptor 1 M1 1 M2 1 M3 1 M4 1 M5 1 CysLT1 receptor 1 FcγRIII 1 +6 more

Biosimilars (1 BLA approved) Click to expand

Biosimilars are biological products highly similar to FDA-approved reference biologics with no clinically meaningful differences in safety, purity, or potency.

OMLYCLO

CELLTRION INC

2025

Generic Drugs (11 ANDA approved) Click to expand

Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).

BECLOMETHASONE DIPROPIONATE

AMNEAL IRELAND LTD

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE